SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool's endovascular Celsius Control System will be featured on Science Channel's "Cool Stuff: How It Works" series. The segment (episode 5) will feature InnerCool's endovascular cooling during a 6-hour brain surgery and is scheduled to air on Friday, April 25, 2008 at 8:00 p.m. (ET/PT). Please visit http://science.discovery.com/tv-schedules/series.html for broadcast dates and times in your area.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2006 Annual Report at http://www.cardiumthx.com/flash/pdf/2006CardiumAnnualReport.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.
Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. For example, there can be no assurance that commercialization
efforts will effectively accelerate InnerCool's patient temperature
modulation business, that product modifications or launches will be
successful or that the resulting products will be favorably received in the
marketplace, that our products or proposed products will prove to be
sufficiently safe and effective, that our products or product candidates
will not be unfavorably compared to competitive products that may be
regarded as safer, more effective, easier to use or less expensive, that
results or trends observed in one clinical study or procedure will be
reproduced in subsequent studies or procedures, that third parties on whom
we depend will behave as anticipated, or that necessary regulatory
approvals will be obtained. Actual results may also differ substantially
from those described in or contemplated by this press release due to risks
and uncertainties that exist in our operations and business environment,
including, without limitation, our limited experience in the development,
testing and marketing of therapeutic hypothermia devices and whether our
efforts to launch new devices and systems will be successful or completed
within the time frames contemplated, risks and uncertainties that are
inherent in the conduct of human clinical trials, including the timing,
costs and outcomes of such trials, our dependence upon proprietary
technology, our history of operating losses and accumulated deficits, our
reliance on collaborative relationships and critical personnel, and current
and future competition, as well as other risks described from time to time
in filings we make with the Securities and Exchange Commission. We
undertake no obligation to release publicly the results of any revisions to
these forward-looking statements to reflect events or circumstances arising
after the date hereof.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc. Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are trademarks of
Tissue Repair Company.
InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM), RapidBlue(TM), CoolBlue(TM) and Accutrol(TM) are trademarks of InnerCool
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved